Tag Archives: NASDAQ:ADHD

Alcobra Receives a Hold from Jefferies

In a report released today, Eun Yang from Jefferies reiterated a Hold rating on Alcobra (NASDAQ: ADHD), with a price target of $1.25. The company’s shares closed last Friday at $1.21, close to its 52-week low of $0.83. According to

Cantor Fitzgerald Gives a Hold Rating to Alcobra

Cantor Fitzgerald analyst Mara Goldstein reiterated a Hold rating on Alcobra (NASDAQ: ADHD) today and set a price target of $1. The company’s shares opened today at $1.08. Goldstein noted: “Development of new drugs carries a high failure rate, either

Alcobra Gets a Hold from Jefferies

In a report released today, Brian Abrahams from Jefferies reiterated a Hold rating on Alcobra (NASDAQ: ADHD), with a price target of $1.25. The company’s shares closed yesterday at $1.14. According to TipRanks.com, Abrahams is a 5-star analyst with an

Cantor Fitzgerald Releases a Hold Rating on Alcobra

In a report released today, Mara Goldstein from Cantor Fitzgerald reiterated a Hold rating on Alcobra (NASDAQ: ADHD), with a price target of $1. The company’s shares opened today at $1.14. Goldstein commented: “Market for ADAIR. At a KOL meeting

Roth Capital Thinks Alcobra’s Stock is Going to Recover

Alcobra (NASDAQ: ADHD) received a Buy rating from Roth Capital analyst Michael Higgins today. The company’s shares closed yesterday at $1.18, close to its 52-week low of $0.83. According to TipRanks.com, Higgins is ranked 0 out of 5 stars with

Is Alcobra’s (ADHD) Fate in the Hands of FDA’s December Feedback?

Healthcare

After reporting a Q3 miss by $0.02 yesterday, emerging pharmaceutical company Alcobra Ltd (NASDAQ: ADHD) shed more than 5% of its share price in a single day and is currently trading at a price of $1.85. The company has been